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Abstract: A porcine calvaria defect study was carried out to
investigate the bone repair potential of three-dimensional
(3D)-printed poly-e-caprolactone (PCL) scaffolds embedded
with nanoporous PCL. A microscopic grid network was cre-
ated by rapid prototyping making a 3D-fused deposition
model (FDM-PCL). Afterward, the FDM-PCL scaffolds were
infused with a mixture of PCL, water, and 1,4-dioxane and
underwent a thermal-induced phase separation (TIPS) fol-
lowed by lyophilization. The TIPS process lead to a nanopo-
rous structure shielded by the printed microstructure (NSP-
PCL). Sixteen Landrace pigs were divided into two groups
with 8 and 12 weeks follow-up, respectively. A total of six
nonpenetrating holes were drilled in the calvaria of each ani-
mal. The size of the cylindrical defects was h 10 mm and Ø
10 mm. The defects were distributed randomly using follow-
ing groups: (a) NSP-PCL scaffold, (b) FDM-PCL scaffold, (c)
autograft, (d) empty defect, (a1) NSP-PCL scaffold 1 autolo-
gous mononuclear cells, and (a2) NSP-PCL scaffold 1 bone
morphogenetic protein 2. Bone volume to total volume was
analyzed using microcomputed tomography (mCT) and histo-
morphometry. The mCT and histological data showed signifi-
cantly less bone formation in the NSP-PCL scaffolds in all
three variations after both 8 and 12 weeks compared to all
other groups. The positive autograft control had signifi-
cantly higher new bone formation compared to all other
groups except the FDM-PCL when analyzed using histo-
morphometry. The NSP-PCL scaffolds were heavily infil-
trated with foreign body giant cells suggesting an
inflammatory response and perhaps active resorption of the
scaffold material. The unmodified FDM-PCL scaffold showed
good osteoconductivity and osseointegration after both 8
and 12 weeks. VC 2013 Wiley Periodicals, Inc. J Biomed Mater Res
Part A: 00A:000–000, 2013.
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INTRODUCTION
Tissue engineering combines methods from materials engi-
neering and biomedical sciences to regenerate tissue using
artiﬁcial constructs.1 Different approaches have been uti-
lized to enhance new bone formation using scaffolds pro-
duced from synthetic and natural materials. Owing to
increased research in construct material and morphology, it
is now possible to implant biodegradable scaffolds which
stimulate bone ingrowth directly.2,3 These features can be
accomplished by using biocompatible and biodegradable
components which end up with no residual scaffold material
and complete healing with autologous bone.4
To improve scaffolds for bone regeneration, a combina-
tion of materials and surface morphology can be utilized to
increase surface biocompatibility, degradation proﬁle of the
scaffold, and mechanical properties.5–7 One way to manipu-
late primarily synthetic polymers into a desired three-
dimensional (3D) structure is using fused deposition model
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(FDM), a rapid prototyping technology, which ensures each
scaffold can be custom-made to accommodate challenges of
different bone void dimensions without loosing the desira-
ble feature from scalable and cost-effective industrial pro-
duction.8 Poly-e-caprolactone (PCL) is one of the most
widely used synthetic polymers in scaffold development and
application within orthopedics. The polymer is highly bio-
compatible and degrades into harmless by-products metabo-
lized in the tricarboxylic acid cycle.4,9 Implementation of
FDM-manufactured PCL scaffolds into clinical practice,
where new bone formation is needed, has already begun.10
To increase surface area for cell adhesion, a newly devel-
oped and patented procedure was used to create a nano-
structured porous (NSP) PCL scaffold.11 A micro- and
nanoporous structure was added to the macroporous FDM-
manufactured scaffold by infusing the macroporous FDM
scaffold with a PCL solution, which was then demixed and
solidiﬁed using thermal-induced phase separation (TIPS)
and lyophilization. This newly developed hierarchically
structured NSP-PCL scaffold holds several hypothetical ben-
eﬁts compared to other scaffolds. The unique combination
of a rapid prototyped and a lyophilized structure adds a
multilevel porous morphology, which ensures a large sur-
face area for cell adhesion and proliferation while mimick-
ing the complex structure of bone to accommodate
differentiation and bone formation. Furthermore, the FDM
component adds a degree of mechanical strength that is
unattainable using TIPS-based fabrication methods alone.
High surface area also holds an advantage for functionaliza-
tion with growth factors like bone morphogenetic protein 2
(BMP-2) or preseeding with stem cells before implantation.
This approach has shown promising results when applied to
similar scaffolds used for cartilage repair.12
The main aim of this study was to assess the osteogenic
potential of the new scaffold in vitro and in vivo hypothesiz-
ing that enlargement of surface area via incorporation of
nanostructured pores into a fusion-deposition-modeled PCL
scaffold would improve its osteogenic potential. In addition,
individual cells in the NSP-PCL will experience a vastly dif-
ferent set of mechanical cues than on a FDM-PCL scaffold.
To test our hypothesis the (a) NSP-PCL scaffold was com-
pared to, (b) a FDM-PCL scaffold, (c) a positive autograft
control, and (d) a negative empty control. Another aim was
to analyze the efﬁcacy of a functionalized (a) NSP-PCL scaf-
fold with either (a1) autologous stem cells or (a2) BMP-2
on bone healing in a calvarial bone defect model in pigs
(Fig. 1).
MATERIALS AND METHODS
Scaffold construction and characterization
The scaffolds were made by FDM fabrication using a Bio-
Scaffolder (SysEng GmbH, Germany). The scaffold material
was the polymer PCL with a molecular weight of 50 kDa
(Perstorp UK, Cheshire, UK). FDM, like any other rapid pro-
totyping technique, allows for a precise control of the scaf-
folds’ porous geometry. In this study, the scaffolds were
built from layered deposition of polymer strands by extrud-
ing molten PCL from an extrusion die with an inner
diameter of 200 mm (ﬁnal ﬁber diameter  175 mm). To
ensure thorough and stable fusion junctions between layers,
the layer thickness was set to 120 mm. The center to center
distance between parallel ﬁbers in each layer was 1000
mm and each layer was angled 105 in relation to the
underlying one to allow for a tortuous and laterally inter-
connected porous network. These scaffolds are hereafter
referred to as FDM-PCL. The scaffolds were subsequently
infused with a homogenous mixture of PCL, water, and 1,4-
dioxane and underwent a TIPS followed by lyophilization.
The polymer concentration was 30 mg PCL/g 1,4-dioxane.
Two different water concentrations were used (0.01 and
0.03 wt %). Higher water concentration resulted in larger
pore sizes. The freeze-drying process resulted in a nano-
structured porous PCL structure within the FDM element of
the scaffolds [Fig. 2(D–F)]. The NSP-PCL scaffold composi-
tion was optimized with in vitro cell studies regarding pore
size and morphology.
Both the FDM-PCL and NSP-PCL scaffolds were sterilized
in vacuum using ethanol concentrations of 96, 70, and 50%,
30 min each, followed by rinsing in sterile water. To
increase surface hydrophilicity, the scaffolds were treated
with 1.25 M NaOH for 16 h, then neutralized in 1 M HCl for
1 h and rinsed in sterile water.
Characterization of scaffolds was performed using scan-
ning electron microscopy (SEM, Nova NanoSEM 600; FEI
Company, Eindhoven, the Netherlands) and microcomputed
tomography (mCT, mCT 40; Scanco Medical AG, Z€urich, Swit-
zerland). The X-ray tomographic microscopy (XTM) studies
were carried out at the experimental station ID19 of the
European Synchrotron Radiation Facility (Grenoble, France)
taking advantage of the high contrast acquired due to the
high brilliance of the X-ray source realized by the synchro-
tron. The XTM image processing and the volume renderings
were determined using isosurface representations and vol-
ume texture renderings generated by the Amira software
from Mercury Computer Systems (Chelmsford, MA). The
theoretical porosity of the NSP-PCL scaffold was calculated
by following equation:
porositytotal5porositydioxane1porosityH2O
5
Vdioxane
Vdioxane1H2O1PCL
1
H2O
Vdioxane1H2O1PCL
(1)
In vitro assessment of scaffold construct
NSP-PCL scaffolds and scaffolds comprising only the TIPS
PCL component (h 5 5 mm, Ø 5 10mm) were seeded with
2 3 106 immortalized human mesenchymal stem cells sta-
bly transduced by a retroviral vector containing the gene for
the catalytic subunit for human telomerase (hMSC-TERT)13
The seeded scaffolds were cultured for up to 22 days at
37C, in a humidiﬁed atmosphere of 5% CO2 in Dulbecco’s
modiﬁed Eagle medium (GIBCO 31966; Invitrogen) supple-
mented with 10% fetal calf serum (GIBCO 10270; Invitro-
gen) [hereafter referred to as proliferation media], or in an
osteoinductive media (OIM) consisting of proliferation
media supplemented with 10 nM dexamethasone (D2915,
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Sigma), 466 mM ascorbic acid-2-phosphate (D2915, Sigma),
and 10 mM b-glycerophosphate (G-9891, Sigma).
To visualize cell ingrowth, transitional sections of scaffolds
comprising only the TIPS component were cut and stained
with hematoxylin and eosin (H&E). Samples of NSP-PCL scaf-
folds were in 70% ethanol and embedded in Technovit 9100V
R
(Heraeus Kulzer, Kulzer Division, Werheim, Germany). Sec-
tions of 7 mm were cut and stained using Goldner’s Tri-
chrome14 and evaluated with light microscopy to visualize
mineralization. For SEM, the constructs were ﬁxed in 2.5%
glutaraldehyde containing 0.1 M sodium cacodylate buffer (pH
7.4) and dehydrated in a graded series of ethanol (50–99%)
before being transferred to a desiccator for air-drying. Con-
structs were analyzed for attachment of cells using SEM with
a low vacuum secondary electron detector.
To assess cell viability, the NSP-PCL were rinsed in
phosphate-buffered saline (PBS) and stained with 2 mM cal-
cein AM and 4 mM ethidium homodimer (EthD-1) in PBS
(Live/Dead VR Viability Kit, Molecular Probes) for 45 min in
the dark. Images were acquired immediately after staining
using a confocal laser scanning microscope 510 Meta (Zeiss
microimaging GmbH, G€ottingen, Germany).
Study design, animal model
A paired study design comparing the intervention groups
with the positive and negative control group within the
same animal was chosen. A cranial bone defect model in
female Danish Landrace pigs (8 months old) was utilized to
compare the six groups. The calvarium was selected due to
the thickness of the porcine calvaria and the trabecular
bone morphology. A total of 16 pigs were equally divided
between the two observation times: 8 weeks (n 5 8) and
12 weeks (n 5 8). Two observation times were chosen to
elucidate bone healing and scaffold degradation over time.
The study was approved by the Danish Animal Research
Inspectorate and conformed to Danish law (application no.
2012-15-2934-00362).
Cell extraction and cultivation
Four weeks before surgery, autologous bone marrow was
aspirated from the proximal tibia into a 50-mL syringe con-
taining 10 mL DMEM with 50 IE heparin. A total of 30 mL
bone marrow was aspirated from each animal. Mono-
nucleated cells were puriﬁed by FicollV
R
gradient centrifuga-
tion (Sigma-Aldrich Co. LLC., St. Louis, MO) and thereafter
FIGURE 1. 3D computed tomography rendering of pig calvaria 2 weeks postsurgery. The groups were randomized between all six holes. Holes
were placed in the back part of the calvaria due to large sinuses in the frontal part. Sutures in the calvaria surface were avoided during surgery.
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cultured in proliferation media for two passages. Subse-
quently, we determined the number of available cells, and
we found that 1.3 3 106 cells was the largest possible num-
ber that ensured a uniform and standardized treatment.
Five days before surgery, 1.3 3 106 cells/NSP-PCL were
seeded and cultivated for 2 days in proliferation media fol-
lowed by 3 days in OIM.
Anesthesia
Anesthesia during bone marrow aspiration and premedica-
tion before surgery was comprised of Zoletil mix 1 mL/10
kg (tiletamin 2.5 mg/mL, zolazepam 2.5 mg/mL, torbugesic
0.5 mg/mL, ketaminol 2.5mg/mL, and rompun 2.5 mg/mL;
Virbac, DK). During the surgery procedure intravenous pro-
pofol (B. Braun Melsungen AG, Melsungen, Germany) 1 mL/
kg/h, and fentanyl (Haldid, Janssen-Cilag A/S, Birkerd,
Denmark) 0.5 mL/kg/h was used.
Surgical procedure
A sharp T-shaped, coronal-sagittal incision was made in the
forehead. Periosteum was dissected and using a wire guide,
three K-wires were drilled perpendicular into the bone. The
middle K-wire in the intended center of the defect, and two
perpendicular K-wires 2 mm lateral to the edges of the
intended defects. Six nonpenetrating defects were created
using a cannulated drill bit (10 mm in diameter and 10 mm
in depth). Autolougous bone from the drill holes was kept
aside for later use. The defects were positioned 10 mm
apart to avoid biological interaction.
The defects were distributed at random using following
groups: (a) NSP-PCL scaffold, (b) FDM-PCL scaffold, (c) auto-
graft (1.12 g harvested from the drill holes), (d) empty
defect, (a1) NSP-PCL scaffold 1 autologous bone marrow
stem cells, and (a2.) NSP-PCL scaffold 1 BMP-2 (1 mg/scaf-
fold from InductOs, Wyeth, Berkshire, UK). Before implanta-
tion 0.67 mL of 1.5 mg/mL BMP-2 solution was administered
to the scaffold in the operation theater. The dose of 1 mg
BMP-2 per defect was guided by the product information,
which states that the applied concentrations should not
exceed 1.5 mg/mL due to potential adverse effects, for exam-
ple, localized edema. In the present study, the volume of the
bone defect was 0.786 cm3. The maximum applicable dose
was therefore 1.18 mg/defect. Visualization of placement of
holes is shown in Figure 1. The soft tissues were reposi-
tioned and sutured. The animals were treated postopera-
tively with systemic antibiotics (Streptocillin; Boehringer
Ingelheim, Ingelheim, Germany, 1mL/10kg) for 3 days. Two
animals from the 12-week group were put down due to
humane endpoint complications unrelated to surgery or
infections. Eight and six animals were killed after 8 and 12
weeks, respectively, using an overdose phenobarbital. After-
ward, the calvaria were resected and frozen to 280C.
Microcomputed tomography
After embedding the bone specimens were scanned by high-
resolution mCT scanning. Cylindrical regions of interest
(ROIs), 10 mm in diameter and a depth of 8 mm were
FIGURE 2. A, 3D mCT rendering of the FDM-PCL scaffold. B and C, SEM visualization of the scaffold surface. The SEM images illustrate an open
structure with large pore size. On high magnification, small indentations indicating spherulite borders in the surface are evident. D, 3D mCT ren-
dering illustrates a denser and more irregular surface structure of the NSP-PCL scaffold. On the SEM images (E and F), the various pore sizes
within the scaffold are evident. The alignment of the microporous structure is unidirectional with small depositions of PCL on the lamellar-like
PCL. The thickness of the three fibers in image (D) measures (from top to bottom) 50.73, 11.97, and 60.11nm.
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chosen. The cylindrical ROIs were found using the carbon
ﬁber guide wires as markers parallel to the drill holes. The
scanned images were rendered in 3D reconstruction, and
computational algorithms were used to calculate bone vol-
ume to total volume (BV/TV) fractions using a calculated
average threshold value of 130. Scanner integrated software
was utilized to perform this analysis.
Histomorphometry
The frozen calvaria were cut in half, dehydrated in ethanol
(70–99%), and embedded in methylmethacrylate. Slices
with a thickness of 7 mm were made on two levels in the
sagittal plane with 400 mm between each level using a
microtome (Polycut E, Reichert-Jung, Heidelberg, Germany).
The samples were stained with Goldner’s Trichrome stain.
Staining for tartrate-resistant acid phosphatase (TRAP) was
performed on NSP-PCL samples to detect osteoclast-like
cells.15
Histomorphometry was performed using Cavalieri point
count technique (CAST-grid system; Olympus Denmark A/S,
Glostrup, Denmark) to quantify the amounts of new bone
and residual scaffold material compared with TV.
Statistics
Comparison analysis was calculated as group average with
standard deviations and compared using repeated measures
analysis of variance using STATA software (Ver. 12.1;
StataCorp LP, College Station, TX) and PRISM (Ver. 6; Graph-
Pad Software, San Diego, CA). Differences between groups
were analyzed using Turkey’s multiple comparisons test. A
p value of <0.05 was considered signiﬁcant.
RESULTS
Scaffold characterization
mCT of FDM-PCL scaffolds showed a successful layer-by-
layer deposition of the polymer. SEM visualized small
grooves in the surface of the PCL. The FDM manufacturing
method created homogenous strings of PCL ﬁbers in a 3D
grid structure [Fig. 2(B,C)].
In the NSP-PCL scaffolds, mCT visualized a homoge-
nous infusion of the NSP component within the FDM-PCL
scaffold [Fig. 2(D)]. The 0.03 [wt%] water concentration
during TIPS proved most suitable, creating a range of
pore sizes from 500 nm to 50 mm evenly dispersed
between the plotted structures. The pore size range was
estimated from XTM reconstructions made on samples
from the scaffold (Fig. 3). By high-magniﬁcation SEM,
even smaller pores were evident but not quantiﬁable
[Fig. 2(F)]. The calculated theoretical porosity of the
NSP-PCL scaffold was calculated to 0.9726. The micro-
scopical porosity caused by dioxane evaporation during
manufacturing was calculated to 0.9399, whereas water
accounted for the nanosized pores, and a porosity of
0.0328.
FIGURE 3. 3D reconstruction of the XTM images visualizing the nanostructures of the NSP-PCL scaffold. Image depicts a highly variable pore
size throughout the construct. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Cell ingrowth and viability in vitro
hMSC-TERTs were seeded on the top surface of TIPS scaf-
folds and migration was observed during culture. On day 1,
the cells adhered mainly to the seeding surface, but at day
7 migration into the scaffold was evident. After 15 days of
culture, a homogenous distribution throughout the entire
scaffold was observed (Fig. 4).
The viability of the distributed cells on the surface of
constructs was further visualized by live/dead staining on
day 7. The images showed a homogenous distribution of
viable cells in the top layer of the scaffold. No dead cells
were observed [Fig. 5(A)].
Mineralization nodules were observed after 22 days of
culture by Goldner’s Trichrome staining, and large areas of
dense matrix indicated active production of protein from
cells. A gradient of increasing differentiation level was
observed with elongated osteoprogenitor cells in the outer-
most areas surrounding round, matrix-producing and fully
mineralized osteoblasts in the central part [Fig. 5(B)].
Microcomputed tomography
After 8 weeks BV/TV in the autograft group was 49.3 6
12% which was signiﬁcantly higher than in all other groups.
Bone formation in the empty defect was 24 6 7%, with no
signiﬁcant difference from the defect with FDM-PCL scaffold
(25.3 6 10%).
The defects with NSP-PCL scaffolds implanted exhibited
a low BV/TV with 5.8 6 2.4% NSP-PCL scaffold, 3.5 6 3.1%
NSP-PCL 1 stem cells and 2.9 6 3.2% NSP-PCL 1 BMP-2
(Fig. 6).
After 12 weeks, BV/TV in the autograft group was
almost the same as in the 8 weeks group at 46.5 6 16%.
This value was still signiﬁcantly higher than all other
groups. The empty defect also kept a steady BV/TV at 23 6
2%. The defect with FDM-PCL increased to 29.3 6 6%, not
signiﬁcantly higher than the empty defect.
In the NSP-PCL groups, no increase in BV/TV was found
with the scaffold alone, BV/TV 2 6 1.6%, or seeded with
stem cells, BV/TV 3.6 6 2.7%. The NSP-PCL 1 BMP-2 group
saw an increase in BV/TV to 10.4 6 10%; signiﬁcantly
higher than NSP-PCL alone.
No signiﬁcant increase in BV was observed between 8
and 12 weeks (Fig. 6).
Histomorphometry
Histomorphometry from 8 weeks showed a signiﬁcantly
higher BV/TV in the autologous bone defect compared to
the empty defect (35.9 6 8.8% vs. 24.7 6 5.5%). The bone
morphology was however the same in both groups, albeit
trabecular thickness was larger in the autologous bone
FIGURE 4.
FIGURE 4. Migration throughout saggital section of TIPS-scaffold after
1, 7, 15, and 22 days visualized by H&E stain. One day after seeding,
cells were concentrated on the surface of the scaffold. Cells did not
get deposited within the scaffold during the seeding procedure, but
were situated in the top 200 mm layer of the scaffold. On day 7 cells
had migrated more than 1 mm down into the scaffold structure and
after 15 days, cells distributed throughout the scaffold (5 mm depth).
The surface cell layer had reached full confluence and the cell density
was increasing from the surface and 1 mm into the scaffold. After 22
days, cell density throughout the scaffold was increased and in
the top layer cell had started to group into clusters. Images are
representative samples from multiple setups (n  3). [Color figure can
be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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defects. No residual autograft material was observed after 8
weeks of implantation. The new bone was particularly situ-
ated at the edges of the defects in the empty defect and
more evenly distributed in the autologous bone defect.
Woven bone had started to remodel into lamellar bone.
In the FDM-PCL group, new bone formation was evenly
distributed throughout the defect. The PCL ﬁbers were
clearly evident throughout the defect, and ﬁlled up a great
portion of what in the autologous bone and empty defect,
respectively, was marrow space.
The FDM-PCL scaffold had a BV/TV of 34.7 6 7.8%, sig-
niﬁcantly higher than the empty defect. Contrary to the mCT
data, no signiﬁcant difference in BV/TV was found between
the FDM-PCL and the autologous bone defects.
In the NSP-PCL group, a large quantity of scaffold mate-
rial was present in the defects.
Most of the scaffold was inﬁltrated by large amounts of
TRAP-positive foreign body giant cells (FBGCs) attached to
the interﬁbrous compounds of the scaffold. The sparse bone
formation was situated randomly throughout the defect. The
trabecular thickness of the bone adjacent to the defect was
increased. BV/TVs were 9.6 6 3.6% NSP-PCL, 8.6 6 5.0%
NSP-PCL 1 stem cells, and 10.5 6 3.5% in NSP-PCL 1
BMP-2 with no signiﬁcant differences between the groups
(Figs. 7 and 8).
In histomorphometry from 12 weeks, bone morphology
and quantity in the autologous bone, empty, or FDM-PCL
defects were similar to the ﬁndings after 8 weeks. However,
FIGURE 5. A, Confocal micrograph of whole scaffold surface after live/dead staining. Green colors represent viable cells with active esterase
activity. Cells were evenly distributed along the surface of the construct. Dead cells are stained red but were not present. B, Histological surface
section after 22 days of in vitro cultivation. The sections were stained with Goldner’s Trichrome. C, Scanning electron micrographs of a cell-
seeded specimen 22 days after seeding with cells represented on the surface. Images are representative samples from multiple setups (n  3).
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
FIGURE 6. Scatter plot diagrams of BV/TV estimated with mCT after 8 (left) and 12 weeks (right). Middle bar represents group average and error
bars represents standard deviations. A significantly higher BV/TV was found in the autograft group compared to all other groups (*). A low BV/
TV was found in all three NSP-PCL groups. The only observation deviating from this finding was NSP-PCL functionalized with BMP-2 where no
significant difference was found compared to the empty defect after 12 weeks (** and ****). After 8 weeks, no difference was found between
the empty defect and the FDM-PCL group. The NP-PCL BV/TV did increase relatively more than in the autograft and empty group between 8 and
12 weeks. At 12 weeks the difference between autograft (46.5 6 16%) and FDM-PCL (29.3 6 6%) was not statistically significant (***).
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more lamellar bone was observed in all three groups, and
the distinctive border between existing bone in the adjacent
calvaria and new bone had diminished. BV/TV for the auto-
graft group was 33.9 6 10.4%, for the empty group 24.9 6
4.8%, and for the FDM-PCL group 32.3 6 2.4%, respectively.
Again, both the autologous bone and the FDM-PCL defects
had signiﬁcantly higher BV/TV than the empty defect. No
signiﬁcant difference was found between the FDM-PCL and
the autologous bone group. In the NSP-PCL groups, a
signiﬁcant difference in BV/TV between the NSP-PCL
FIGURE 7. Scatter plot diagrams of BV/TV found by histomorphometry. Middle bar represents group average and error bars represents standard
deviations. No significant difference in BV/TV was found between Autograft and FDM-PCL was found at any of the two time points (*, **, and
***). BV/TV was significantly higher in the FDM-PCL group compared to the empty defect, after 12 weeks (***). All the NSP-PCL groups at both
time points had significant lower BV/TV compared to the three other groups (****). After 12 weeks, a significantly higher BV/TV was found in
the NSP-PCL 1 BMP-2 compared to the pure NSP-PCL (*****).
FIGURE 8. Representative images of histological samples stained with Goldners Trichrome stain after 8 weeks. 1, Empty defect, (2) autograft, (3)
FDM-PCL, and (4) NSP-PCL. Image (5) is a higher magnification of the NSP-PCL image. 6, NSP-PCL sample stained with tartrate-resistant acid
phosphatase (TRAP). TRAP-positive cells, indicated by arrows, are shown in red. In the empty, autograft and FDM-PCL histological sections,
marrow space (M) and newly formed bone (B) was evenly dispersed throughout the defect. The fibers (F) in the FDM component of the FDM-
PCL and NSP-PCL scaffold were easily identified as empty of translucent gaps in the specimens. The TIPS compound (T) of the NSP-PCL scaffold
was omnipresent in the NSP-PCL specimens as an opaque mesh-like structure with FBGCs highly represented throughout the material. A tend-
ency toward larger presence of FBGCs at the edges of the defect was observed. The TRAP stained samples visualized a high concentration of
TRAP-positive cells on the surface of the TIPS compound. [Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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(4.7 6 1.6%) and the NSP-PCL 1 BMP-2 (15.0 6 3.6%)
was found. No signiﬁcant difference was found between the
NSP-PCL 1 stem cells (9.0 6 4.7%) and the two other
groups (Fig. 7).
Scaffold degradation
The degradation of scaffold material was quantiﬁed in the
histological sections between the two time points. In vivo
degradation of the scaffold material was on average 18.6%
in the NSP-PCL groups, which caused a signiﬁcant drop in
scaffold volume. In the FDM-PCL group, only 5.4% of the
scaffold volume degraded between 8 and 12 weeks with no
signiﬁcant difference between the time points (Fig. 9).
DISCUSSION
The scaffolds used in this study have been manufactured
using a highly customizable backbone structure, which can
be three-dimensionally restructured to enhance osseointe-
gration. This study primarily showed a lack of new bone
formation when the NSP technology was applied to a PCL
scaffold. It also showed a discrepancy between bone form-
ing potential of the NSP-PCL scaffold between in vitro and
in vivo settings. The NSP-PCL scaffold showed promising
results from qualitative studies using hMSC-TERT cells in an
in vitro environment, but almost no bone ingrowth was evi-
dent after 8 or 12 weeks in a large in vivo bone defect. The
FDM-PCL scaffolds, however, did show ﬁne osseointegration,
and better bone healing potential than the negative control,
though not as pronounced as the positive autograft control.
The scaffold made purely of FDM-PCL showed a moder-
ate osteoconductive effect after 8 weeks compared to the
negative control. After 12 weeks, no signiﬁcant difference in
BV/TV between autograft and FDM-PCL existed, suggesting
excellent osseointegration and biocompatibility on par with
comparable PCL scaffolds.16 The large pore size of this scaf-
fold resulted in bone ingrowth throughout the void.
It was initially suggested by Hulbert et al.17 in 1970,
that pore sizes ranging between 100 and 400 mm was the
optimal size for bone tissue ingrowth. It was later shown,
that pore size can be more or less dependent on which type
of progression toward ossiﬁcation method the scaffold is
aiming for. Small pore sizes (below 100 mm) stimulate chon-
drogenesis and subsequently ossiﬁcation, whereas pore
sizes above 100 mm stimulate direct ossiﬁcation.18–20 It is
known that varying pore sizes can steer mesenchymal stem
cells into different directions both regarding migration, pro-
liferation, and differentiation.21 We hypothesized that by
making a highly variable pore size range, the scaffold would
mimic the complex architecture of bone matrix, further
enhancing the ossiﬁcation process. The presented qualitative
and unpresented preliminary quantitative evaluation of
hMSC-TERTs migration into the scaffold in vitro demon-
strated a homogenous distribution of cells after 14 days.
The hMSC-TERTs have previously been used to assess cell
migration into similar scaffolds in vitro.22 In the in vivo
study, cell migration toward the center of the NSP-PCL scaf-
folds was evident, but besides few bone forming cells, large
quantities of multinucleated foreign body cells were present
suggesting that a phagocytic response was stimulated. If
this was the result of hypoxia alone, a trend toward forma-
tion of connective tissue and cartilaginous tissue would be
expected. The ﬁndings however suggest that NSP-PCL eli-
cited a foreign body response. Since scaffold degeneration
was less evident in the FDM-PCL group, initiation of this
phagocytic inﬂammatory response could be due to the mor-
phology of the TIPS part of the scaffold. This response was
so pronounced that no difference between the BV/TV in the
three NSP-PCL groups were evident, despite both BMP-2
and MSCs showing additive effect toward new bone
FIGURE 9. Histogram showing the amount of scaffold material (PCL) relative to the total volume (PCL/TV), measured with point count technique
on histological samples. Error bar represent positive SD. A relative lower amount of PCL was found when BMP-2 was added to the scaffold
compared to the other two NSP-PCL groups at both time points. When mononuclear cells where added to the scaffold a relative smaller amount
of PCL was measured compared to the unmodified NSP-PCL at both time points. No significant differences in PCL/TV were found between the
groups. An average decrease in PCL/TV of 18.6% was found between 8 and 12 weeks in the NSP-PCL groups, compared to a 5.4% decrease in
the FDM-PCL group.
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formation on similar types of scaffolds.23–25 These ﬁndings
suggest that scaffold morphology and ultimately low pore
size can inhibit new bone formation and instead cause a
sustained inﬂammatory response. These observations are in
agreement with a previous report that describes that a pore
size of 0.6 mm hinders cellular ingrowth and is likely to
evoke a foreign body response.26 In that article, cells, and
inﬂammatory cells in particular, were concentrated on the
surface of the implant and encapsulated this foreign body. It
is entirely possible that a similar mechanism occurs within
the NSP-FDM scaffolds in the present study. This argument
is supported by the fact that no foreign body response was
observed in the FDM-PCL group. BMSCs are known to pos-
sess immunomodulatory properties which target a multi-
tude of different cell types involved in the immune
response.27 The immune response after implantation of
NSP-PCL scaffolds may therefore differ between cell-loaded
and pure scaffolds. In this article, our observation of FBGCs
was of qualitative nature only. However, we did not observe
an obvious difference in FBGCs or other signs of inﬂamma-
tion between the cell-loaded and pure NSP-PCL group. In
this article, the period of in vitro cell culture before implan-
tation of the cell-loaded scaffold was intentionally kept
short to resemble the clinical setting in which time before
surgery is constrained (i.e., tumor revision and trauma sur-
gery).” However, a longer in vitro period than the applied 2
1 3 days could potentially have enhanced cellular penetra-
tion into the scaffold before implantation. It remains specu-
lation whether this alternative approach would have been
advantageous for the outcome in vivo.
In this article, we chose to stimulate the cells with
osteogenic media to augment direct ossiﬁcation after
implantation of the cell-loaded scaffold. The rationale
behind this approach was that calvarial bone healing is the-
oretically mediated via intramembranous ossiﬁcation rather
than endochondral ossiﬁcation. However, endochondral ossi-
ﬁcation has also been observed in calvarial bone healing
according to Sun et al.28 Hence, prestimulation of the cell-
loaded scaffolds with chondrogenic media could be worth-
while to investigate in the setting of calvarial bone healing
in future studies.
The degradation of the PCL backbone of the scaffolds is
intended to happen gradually over a period of 6 to 12
months. To accomplish this, we used a PCL with molecular
weight of 50 kDa, which ensures a favorable degradation
proﬁle without compromising mechanical properties during
bone ingrowth and remodeling.29 It is widely accepted that
the primary degradation of PCL is through degradation and
erosion involving hydrolytic cleavage of the polymer back-
bone only at its surface.30–32
A relatively high degradation (20%) of the scaffold vol-
ume was found between 8 and 12 weeks; a higher degrada-
tion rate than in similar studies.33 This could be due to the
large surface area and therefore surface degradation
through hydrolytic cleavage. Furthermore, it is known that
macrophages take active part in the degradation of espe-
cially particulate PCL through phagocytosis.34 This could be
the connection between the high degradation rate of the
delicate NSP structure and the cellular response toward
inﬂammation instead of bone formation. The relatively
higher degradation of PCL in both the group with added
BMP-2 and stem cells after 8 weeks suggests that a cellular
response could be the cause of enhanced degradation. Theo-
retically, stem cells representing a larger potential phagocy-
totic cell pool as well as the well-known potential of BMP-2
to recruit osteoclast-like cells35–37 could both explain the
observed acceleration of scaffold degradation.
The pig was the animal of choice for this experiment
owing to its bone regeneration rate (1.2–1.5 mm/day) being
comparable to that of humans (1.0–1.5 mm/day).38 The cal-
varium represents a large surface, easily accessible and with
trabecular bone with at thickness suitable for defects. How-
ever, drawbacks include a lack of mechanical load in the
test period, and a high standard deviation within the empty-
defect group suggests variability between bone healing
potential depending on position of defect in the calvaria.
The high standard deviation is consistent with reports by
Schlegel et al.38 in this model. The dependency of bone heal-
ing capacity upon positioning of the bone defect within the
same animal is currently under investigation at our
laboratory.
Scaffolds created by FDM have a large potential in indi-
vidualized tissue engineering. Scaffolds can be created from
a 3D rendering of a CT or MRI scan to accommodate a par-
ticular bone void. However, creating bioactive constructs is
a multidisciplinary challenge. Results found in the lab need
to be translated into more clinical relevant studies before
clinical application can be considered. The discrepancies
between in vitro and in vivo results in this study emphasize
the importance of animal studies in translational medicine.
CONCLUSIONS
The new NSP-PCL scaffold developed to mimic the complex
multisized porous structure of bone was tested in vitro and
in vivo. Osteogenic potential and high cell viability were
observed in vitro, but were not found after translation into
a large animal model. Instead, acceleration of scaffold degra-
dation, probably due to inﬁltration of FBGCs was observed.
Neither functionalization of the NSP-PCL scaffold with auto-
logous MSCs nor BMP-2 stimulated bone formation. The
unmodiﬁed FDM-PCL scaffold showed good osteoconductiv-
ity and osseointegration after both 8 and 12 weeks empha-
sizing this scaffold as a base for tests of other modiﬁcations
in the future. This study underlines the importance of trans-
lation of new concepts into animal models before imple-
mentation into clinical trials.
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